View Author
patient hepatitis treatment hepatitis c study interferon ribavirin liver response therapy level genotype diabetes mellitus virological diabetes hepatocellular carcinoma effect hepatitis c patients cirrhosis fibrosis mellitu analysis hepatitis c virus infection responder virus chapter virological responders virological response hepatology group outcome transplantation factor table model survival cohort hepatocellular carcinoma disease 24 weeks combination placebo brosi month graft monotherapy combination therapy antipsychotic liver transplantation development recurrence trial serum insulin follow-up event il 28b genotype stage insulin resistance hcv infection figure failure result netherland 48 weeks regression interferon therapy mortality baseline hcv rna increase pegylated interferon hospital donor platelet count ratio non-responder fracture
10 Most Recent Publications
|
Coumarin-induced intramural hematoma of the duodenum: Case report and review of the literature
(Article)
Veldt, B.J. Haringsma, J. Florijn, K.W. Kuipers, E.J. |
2011-03-01
|
|
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection
(Article)
Charlton, M.R. Thompson, A. Veldt, B.J. Watt, K.D.S. Tillmann, H. Poterucha, J.J. Heimbach, J.K. Goldstein, D. Mchutchison, J. |
2011-01-01
|
|
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
(Article)
Pouwels, S. Lalmohamed, A. Souverein, P. Cooper, C. Veldt, B.J. Leufkens, H.G.M. Boer, A. de Staa, T. van Vries, F. de |
2010-01-01
|
|
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C
(Article)
Veldt, B.J. Poterucha, J.J. Watt, K.D.S. Wiesner, R.H. Hay, J.E. Rosen, C.B. Heimbach, J.K. Janssen, H.L.A. Charlton, M.R. |
2009-06-01
|
|
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection
(Article)
Veldt, B.J. Poterucha, J.J. Watt, K.D.S. Wiesner, R.H. Hay, J.E. Kremers, W.K. Rosen, C.B. Heimbach, J.K. Charlton, M.R. |
2008-11-01
|
|
Reply
(Article)
Veldt, B.J. Janssen, H.L.A. |
2008-10-01
|
|
Long-term Clinical Outcome of Treatment for Chronic Hepatitis C
(Doctoral Thesis)
Veldt, B.J. |
2008-06-13
|
|
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
(Article)
Veldt, B.J. Chen, W. Schalm, S.W. Janssen, H.L.A. Heathcote, E.J. Wedemeyer, H. Reichen, J. Hofmann, W.P. Knegt, R.J. de Zeuzem, S. Manns, M.P. Hansen, B.E. |
2008-06-01
|
|
Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C
(Article)
Veldt, B.J. Vliet, H.J. van der Janssen, H.L.A. Nieuwkerk, C.M.J. van Blomberg, B.M.E. von Vlierberghe, H. van Gerken, G. Nishi, N. Hayashi, K. Scheper, R.J. Knegt, R.J. de Eertwegh, A.J.M. van den |
2007-09-01
|
|
Severe allergic eczema due to pegylated α-interferon may abate after switching to daily conventional α-interferon [1]
(Article)
Veldt, B.J. Schalm, S.W. Janssen, H.L.A. |
2007-04-01
|
